Dr. Leopold Sellner | EBMT 2018 | Idelalisib before allogeneic stem cell transplantation


  • Dr Sellner describes a retrospective study by the EBMT Lymphoma Working Party on safety and efficacy of idelalisib use before allogeneic stem cell transplantation (ASCT) in follicular lymphoma.
  • He explains that the results were in line with previous similar studies in lymphoma. Progression-free survival at 12 months was 70%.
  • The main findings of the study showed that idelalisib before ASCT was safe and it was an efficient bridging drug.
44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, PT
Doctor Leopold Sellner, University of Heidelberg, Heidelberg, DE


Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF